Ronald Harold Wilfred Cooper - 24 Oct 2022 Form 4/A - Amendment Insider Report for ALBIREO PHARMA, INC.

Role: President and CEO, Director
Signature: /s/ Jason Duncan, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 24 Oct 2022
Net transactions value: -$17,991
Form type: 4/A - Amendment
Filing time: 09 Jan 2023, 17:40:07 UTC
Date Of Original Report: 25 Oct 2022
Previous filing: 25 Jul 2022
Next filing: 09 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALBO	Common Stock	Sale	$17,991	-919	-1.5%	$19.58	58,501	24 Oct 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2	Represents 31,106 shares of common stock and 27,395 restricted stock units. Includes 534 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2019; 483 shares of common stock acquired under the ESPP on November 30, 2019; 1,205 shares of common stock acquired under the ESPP on May 31, 2020; and 818 shares of common stock acquired under the ESPP on May 31, 2021.

Content

Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Represents 31,106 shares of common stock and 27,395 restricted stock units. Includes 534 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2019; 483 shares of common stock acquired under the ESPP on November 30, 2019; 1,205 shares of common stock acquired under the ESPP on May 31, 2020; and 818 shares of common stock acquired under the ESPP on May 31, 2021.

Remarks:

This amended Form 4 is being filed solely to report the acquisition of an aggregate of 3,040 additional shares of common stock under the ESPP on May 31, 2019, November 30, 2019, May 31, 2020 and May 31, 2021, as described in footnote 2 above.